Management of venous thromboembolism (VTE) in patients in advanced cancer can be difficult due to the
increased risk of recurrent and extending VTE despite therapeutic anticoagulation, and of bleeding due to or
exacerbated by anticoagulation. Currently, best practice is long term administration of low molecular weight
heparin (LMWH), but a recurrent VTE and bleeding rate remains, and some patients have contra-indications
to anticoagulation. Newer anticoagulants such as oral anti-thrombin agents and biotinylated idrapurinux
may have a role in the future.Management of venous thromboembolism (VTE) in patients in advanced cancer can be difficult due to the
increased risk of recurrent and extending VTE despite therapeutic anticoagulation, and of bleeding due to or
exacerbated by anticoagulation. Currently, best practice is long term administration of low molecular weight
heparin (LMWH), but a recurrent VTE and bleeding rate remains, and some patients have contra-indications
to anticoagulation. Newer anticoagulants such as oral anti-thrombin agents and biotinylated idrapurinux
may have a role in the future
